MAPS Public Benefit Corporation (MPBC) is a wholly-owned subsidiary of Multidisciplinary Association for Psychedelic Studies (MAPS). The special purpose of MPBC is to balance income from the legal sale of MDMA with the social benefits of MAPS’ mission by serving as a vehicle for conducting MAPS’ psychedelic and marijuana research initiatives.
MPBC’s primary work is completing Phase 2 studies of MDMA-assisted psychotherapy for PTSD, and preparing for the Phase 3 clinical trials required to develop MDMA-assisted psychotherapy into an approved treatment for PTSD. MAPS will continue to conduct education and harm reduction projects, to raise funds for MPBC projects, and serve as parent organization and sole funder of MPBC. MPBC was incorporated on December 19, 2014.
MPBC is a key part of MAPS’ strategy to become a sustainable non-profit organization. MAPS currently projects FDA and European Medicines Agency (EMA) approval for the prescription use of MDMA-assisted psychotherapy for PTSD in 2021. Once MDMA-assisted psychotherapy is approved, MPBC will manage prescription sales of MDMA, a taxable activity that cannot remain inside MAPS’ 501(c)(3) designation. Research expenses incurred by MPBC can be used to reduce taxes on income received by MPBC from legal sales of MDMA. Income from prescription sales of MDMA will help fund further research and educational projects in accordance with MAPS’ mission, reducing MAPS’ reliance on donations over the long term.
The MPBC team is led by Amy Emerson (Executive Director/Director of Clinical Research), who has managed MAPS’ clinical research programs since 2009. The MAPS’ clinical research staff have also joined the MPBC team. The MPBC Board of Directors is appointed by the MAPS Board of Directors, and currently includes Rick Doblin, Ph.D. (MAPS Founder and Executive Director), Allen Hopper (American Civil Liberties Union), and Matt Neal (Amgen).